Expression of CD44v9-containing isoforms (CD44v9) on myeloma plasma cells correlates with unfavorable prognosis, suggesting that CD44 variant molecules are involved in the disease process. In this study, the presence of CD44v on B cell lines from different stages of development was analyzed by flow cytometry and a role in adhesion to stromal cells from different tissues was evaluated in in vitro binding assays. CD44v3, v6 and v9 isoforms were exclusively expressed on plasma cell lines and CD44v9 expression correlated with IL-6-dependent plasma cell growth. Binding studies using CD44 isoformspecific reagents showed that CD44v6 and CD44v9 were involved in binding to bone marrow stromal cells, but not to in vitro synthesized ECM or hyaluronic acid. CD44v9-mediated plasma cell binding resulted in a significant induction of IL-6 secretion by bone marrow stromal cells. Large differences in quantitative plasma cell binding to stromal cells from different tissues were observed. These, however, could not be related to a differential use of CD44v in these binding processes. The role of CD44v9 in adhesion induced IL-6 secretion and its preferential expression on IL-6-dependent plasma cell lines may explain the previously observed correlation between CD44v9 expression and adverse prognosis in multiple myeloma.
Introduction
Multiple myeloma is a hematological malignancy characterized by the presence of monoclonal plasma cells in the bone marrow (reviewed in Ref. 1) . Growth of tumor cells at this preferential site suggests that unique interactions with local elements are crucial for the pathophysiology of the disease. Several adhesion molecules are present on myeloma plasma cells; these include: CD44, VLA-4, VLA-5, LFA-1, MPC-1, CD54, CD56, CD58, Rhamm and, the recently described, 86-kDa subunit of the Ku autoantigen. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] These molecules allow tumor cells to make contact with cellular and extracellular matrix (ECM) components present in the marrow environment. Interaction between myeloma tumor cells and bone marrow stromal cells or osteoblasts leads to production of IL-6 production by these cells. 7, 12, 13 IL-6 is the major growth and survival factor for tumor cells in vitro and in vivo.
14 In addition to playing a possible role in homing and localization in the bone marrow, adhesion molecules are therefore involved in the regulation of myeloma tumor growth and survival.
CD44 is a family of glycoproteins that share the CD44 stan- dard molecule (CD44s), which is a common backbone encoded by 10 exons (1s-10s). Additional isoforms are generated at the RNA level via alternative splicing of one or more variable exons (1v-10v), ultimately resulting in the introduction of additional stretches of extracellular protein in the CD44s. This results in the potential creation of a vast number of different CD44v molecules. 15 Recently, we reported that CD44 variant isoforms containing domain v9 (CD44v9) are associated with progressive disease and a short survival in multiple myeloma, 16, 17 and that CD44v10 is associated with stable disease. 17 This suggests that CD44 variant isoforms (CD44v) are somehow involved in the disease process. Many different functions have been ascribed to CD44. For example, CD44 mediates cell-cell and cell-extra cellular matrix (ECM) interactions, 18 is involved in cell motility, 19 regulates early lymphopoiesis, 20 and is involved in lymphocyte activation, 21, 22 induction of cytokines 23 and apoptosis. 24 Furthermore, it has been shown, using in vivo model systems, that CD44 promotes tumor metastasis and cell growth. 24, 25 The presence of CD44v on certain hematological and solid tumors correlates with tumor progression, bad prognosis and short overall survival, [26] [27] [28] suggesting that CD44 family members play an important role in tumor pathophysiology. It is, however, unclear how and what part of CD44 mediates these effects since not all of these can be attributed to the ability of CD44s to bind ECM component hyaluronic acid (HA) 29 or other ligands. [30] [31] [32] [33] [34] [35] Here, the expression of CD44v on B cell lines from different stages of development and their potential role in adhesion to stromal cells from different tissues was investigated.
Materials and methods

Cultures of adherent cells
Following informed consent, normal bone marrow aspirates were obtained from healthy individuals that were allogeneic bone marrow transplant donors or from patients that underwent coronary bypass surgery. Myeloma bone marrow was obtained from stage III patients, according to the criteria of Salmon and Durie. 36 Myeloma patients were divided into two catagories: patients in quiescent stage of the disease (stable disease) and progressive disease as previously defined. 17 Following informed consent tonsil and splenic cells were obtained from children undergoing tonsillectomy or from heart transplant donors, respectively. The specimens were dissected from the capsule, minced into small fragments and washed in culture medium. Mononuclear cells obtained from bone marrow aspirates, tonsil and spleen were obtained by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density centrifugation. Cells were cultured in DMEM, supplemented with 10% FCS, 100 IU/ml penicillin, 100 g/ml streptomycin and 10 M ␤2-mercaptoethanol. To obtain enough cells to perform the adhesion experiments adherent cells were employed after the fourth passage. All adhesion experiments described in this paper were performed using adherent cells obtained from myeloma patients with progressive disease, unless stated otherwise. The phenotype of these cells has been described before. 7 Adherent cells derived from the bone marrow will be referred to as bone marrow stromal cells.
Cell lines
B cell lines used in this study included: pre-B cell lines Reh (American Tissue Culture Collection (ATCC, Manassas, VA, USA)) and BSM (ATCC), Epstein-Barr virus transformed B cell lines APD and JY, 37 Burkitt lymphoma cell lines Daudi (ATCC) and Namalwa (kindly provided by Dr Jackson, Molecular Immunology Group, University of Oxford, Oxford, UK), plasmablastoid cell lines Fravel, ARH-77 and HS-Sultan (all ATCC). Plasma cell lines analyzed in this study included OPM-1 (kindly provided by Dr Katagiri, Dept of Medicine, Ohtemae Hospital, Osaka, Japan), OPM-2 (German Collection of Microorganisms and Cell Cultures (GCMC, Braunschweig, Germany)), L363 (GCMC), RPMI-8226 (ATCC), IM-9 (ATCC), NCI-H929 (ATCC), UM-1 and the IL-6-dependent plasma cell lines U266 (ATCC), UM-2, 38 UM-3,
38
UM-6 (established in our laboratory), FLAM-76 39 and XG-1.
40
Cell lines were cultured in RPMI-1640 supplemented with 10% FCS, 100 IU/ml penicillin, 100 g/ml streptomycin and 10 M ␤2-mercaptoethanol. Recombinant human IL-6 (1.25 ng/ml; Roche, Almere, The Netherlands) was added to the culture medium of IL-6-dependent cell lines.
Antibodies and fusion proteins
The following monoclonal antibodies (mAbs) were used for flow cytometric analyses of surface antigen expression: antiCD44s (BMS113, IgG 1 ), anti-CD44v6 (BMS116, IgG 1 ), antiCD44v10 (BMS119, IgG 1 ) (all Roche), anti-CD44v4 (11.10, IgG 2a ), 41 anti-CD44v7 (LN7.1, IgG 1 ), 42 anti-CD44v9 (11.24, IgG 1 ), 41 anti-CD44v3 (IgG 2b ) (R&D Systems, Abingdon, UK) and anti-VLA-4 (HP 2/1, IgG 1 , a kind gift from Dr F SanchezMadrid, Dept Immunologia, Hospital Princesa, Madrid, Spain) and FITC-labeled goat anti-mouse IgG subclass antibodies (Southern Biotechnology Associates, Birmingham, AL, USA). In the adhesion assays the following mAbs were used: antiCD44s (515), 43 anti-CD44v3 (IgG 2b ) (R&D Systems), antiCD44v4 (11.10, IgG 2a ), 41 anti-CD44v6 (11.9, IgG 1 ), 41 antiCD44v7 (LN7.1, IgG 1 ), 41, 42 anti-CD44v9 (11.24, IgG 1 ), 41 antiCD44v10 (BMS119, IgG 1 ) (Roche) and anti-VLA-4 (5D5, a kind gift from Dr G Gaudernack, Institute of Transplantation, National Hospital, Oslo, Norway). Titration experiments performed with antibodies and fusion proteins showed optimal blocking of adhesion by 1-5 g/ml for antibodies and 10-25 g/ml for fusion proteins. In the adhesion inhibition studies saturating amounts of antibodies (10 g/ml) and fusion proteins (50 g/ml) were used. The fusion proteins employed in these experiments (CD44v3-v4-GST, CD44v6-GST, CD44v8-v9-v10-GST and CD44v10-GST) were extensively dialyzed against RPMI-1640 and have been described before. 41 
Flow cytometry
Antibody staining and protocols for flow cytometric analysis (FACScan; Becton Dickinson, Erembodegem-Aalst, Belgium) of surface antigen expression have been previously described. 7, 16, 17 Briefly, cells were incubated with primary antibodies for 30 min at 4°C, followed by a 30 min incubation period with the relevant FITC-labeled goat anti-mouse IgG subclass antibodies. Cells were washed in PBS containing 1% BSA and 0.02% sodium azide between stainings. Flow cytometric results are expressed as fluorescence ratios (FR) as has been previously described. 17 These are the ratios between the mean fluorescence intensity of the primary antibody and isotype control stained cells.
Adhesion assays Flow cytometric adhesion assay (FCAA):
Adhesion to stromal cells was quantified using a flow cytometric adhesion assay (FCAA) as previously described. 44, 45 Stromal cells were trypsinized and plated in 48-well tissue culture plates at a density of 10 4 cells per well and subsequently incubated overnight at 37°C with 5% CO 2 . Plasma cells (5 × 10 4 per well, in triplicate) were allowed to adhere to stromal cells for 2 h at 37°C and 5% CO 2 in the presence of control or blocking antibodies or fusion proteins (for concentrations see above). After removal of non-bound plasma cells, the cells remaining in individual wells were trypsinized and analyzed by flow cytometry. Plasma cells were distinguished from stromal cells by morphologic criteria (forward scatter and side scatter) as previously described. 7, 44, 45 From each sample 3000 cells were measured and the ratio of adherent plasma cells to stromal cells was calculated. Results from the triplicate wells were used to calculate a mean adhesion ratio. The percentage binding was defined as the percentage of binding which occurs in the presence of antibodies against adhesion molecules or fusion proteins calculated relative to binding in the presence of control antibodies or fusion proteins set at 100%. The percentage of binding inhibition was 100% -the percentage binding as defined above. For the quantitative analysis of plasma cell binding to stromal cells from various tissues, plasma cells were allowed to adhere as described above. Non-adherent cells were subsequently collected and counted. The percentage of bound plasma cells was calculated as follows: percentage bound cells = ((input cells) − ((non-adherent cells)/(input cells)) × 100.
Adhesion to ECM:
In vitro synthesized ECM from bone marrow stromal cells obtained from myeloma patients with progressive disease, was prepared in 96-well plates. To this end, stromal cells were cultured until confluency and were subsequently removed by a 30 min incubation with Triton X-100 (0.5% in H 2 O at room temperature). Triton treatment removes cells effectively by solubilizing lipid membranes, but leaves ECM matrix components such as fibronectin, laminin, von Willebrand factor and collagens intact so that they are able to bind to adhesive receptors which are expressed on cells. [46] [47] [48] Triplicates of 10 5 cells/well were adhered to rinsed ECM under static conditions in the presence of adhesion blocking or control antibodies (10 g/ml) for 1 h at 37°C. Non-adherent cells were removed and viable adherent cells were quantified using the MTT assay.
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Adhesion to HA:
Using 1-ethyl-3(3-dimethylaminopropyl) carbodiimide (EDC; Pierce, Rockford, IL, USA) hyaluronic acid (HA) (Sigma, St Louis, MO, USA) was coated to Covalink NH plates (Nunc, Naperville, IL, USA). 50 To this end, an HA stock solution (10 mg/ml in H 2 O) was diluted to 100 g/ml in H 2 O (working solution). One hundred l of the working solution together with 50 l EDC and 50 l HCL (0.4 mM) were added to individual wells of a 96-well plate. After a 2 h incubation period at RT the coated plates were washed three times with PBS supplemented with NaCl (2 M) and MgSO 4 (40 M) and twice with PBS and were stored at 4°C for further use. During the adhesion assay triplicates of 10 5 cells were allowed to adhere to HA-coated wells in the presence or absence of antibodies (10 g/ml) under static conditions for 1 h at 37°C. Non-adherent cells were removed and viable adherent cells were quantified using the MTT assay. 49 
IL-6 induction
IL-6 secretion by bone marrow stromal cells was induced following plasma cell co-culture as previously described. 7 Stromal cells from bone marrow of myeloma patients with aggressive disease were trypsinized and plated in 48-well tissue culture plates at a cell density of 10 4 per well. After overnight incubation at 37°C and 5% CO 2 , 5 × 10 4 plasma cells were added and the stromal cells and the plasma cells were co-cultured in the presence of antibodies against CD44v9 or isotype-and subclass-matched antibodies (10 g/ml). After 5 days of co-culture supernatants were harvested and analyzed by ELISA for IL-6 content as previously described. 7 All experiments were performed in quadruplicate.
Statistical analysis
The association between IL-6 dependency and expression of CD44v3, v6 or v9 on plasma cell lines was tested using the Fisher exact test. A two-sided paired Student's t-test was used to compare differences between plasma cell binding in the presence of blocking or control antibodies. A two-sided unpaired Student's t-test was used to compare differences between plasma cell binding and binding inhibition to stromal cells of different origin. 
Results
Expression of CD44 family members on B cell lines at different stages of development
Involvement of CD44v in the binding of plasma cells to bone marrow stromal cells
Plasma cell binding to bone marrow stromal cells induces IL-6 secretion and reflects the importance of adhesion in the regulation of myeloma tumor growth. 7, 12 Since all IL-6-dependent plasma cell lines expressed CD44v, their involvement in adhesion to bone marrow stromal cells was investigated. XG-1 cells were allowed to adhere to stromal cells in a static adhesion assay and the involvement of VLA-4, CD44s and CD44v3, v4, v6, v7, v9, v10 in the binding process was evaluated. The results presented in Figure 1a show that antibodies directed against CD44s and VLA-4 block 65.0% ± 2.2 and 14.5% ± 5.4 of the binding, respectively. Additionally, also antibodies directed against CD44v6 and v9 significantly inhibited XG-1 binding to stromal cells by 21.1% ± 3.0 and 29.6% ± 2.5, respectively. Antibodies directed against CD44v3 induced a small but significant binding inhibition of 12.3% ± 2. + plasma cell lines NCI-H929 and U266 by 21.9% ± 4.5 and 19.1% ± 4.6, respectively (Figure 1c and d) . Surprisingly, binding of U266 was not inhibited by anti-CD44s antibodies (Figure 1d) . A background value of 10% adhesion inhibition was deduced from adhesion experiments using CD44v-negative cell lines; adhesion inhibition percentages less than 10% were therefore considered to be negative.
Binding inhibition studies using CD44 fusion proteins gave similar results as those obtained using specific CD44v antibodies. CD44v6-and CD44v8-9-10-GST fusion proteins significantly inhibited the binding of XG-1 to bone marrow stromal cells (42.1% ± 5.0 and 32.6% ± 7.0, respectively), whereas CD44v3-v4-and CD44-v10-GST fusion proteins did not significantly interfere with adhesion ( Figure 2) . Overall, these data show that CD44v6 and CD44v9 are involved in adhesion of plasma cells from cell lines to bone marrow stromal cells.
Involvement of CD44v6 and v9 in the binding of plasma cells to ECM and HA
ECM contains important ligands for membrane-bound adhesion molecules present on plasma cells, including CD44 molecules. We evaluated and compared the involvement of CD44s, VLA-4, CD44v6 and v9 in the binding of XG-1 cells to bone marrow stromal cells, plastic immobilized HA and in vitro synthesized ECM derived from bone marrow stromal cells (for isolation techniques see Materials and methods) (Figure 3 ). Binding to bone marrow stromal cells was significantly inhibited by antibodies directed against CD44s, VLA-4 and CD44v6 and CD44v9, whereas binding to ECM was dependent on both CD44s and VLA-4-mediated interactions, 
Involvement of CD44v6 and v9 in the binding of plasma cells to adherent cells from various tissues
Little is known concerning molecules involved in myeloma plasma cell localization in the bone marrow environment. Adhesion experiments were performed using stromal cells from various tissues to study selective usage of CD44v molecules in plasma cell adhesion. For this purpose, stromal cells were cultured from different tonsils (n = 6), spleens (n = 5) and bone marrow aspirates from healthy individuals (n = 10) and myeloma patients with stable (n = 10) or progressive disease (n = 22). Large differences were observed in binding of XG-1 cells to identically cultured stromal cells from different tissues (Figure 4 ). Quantitative binding of XG-1 to stromal cells derived from tonsil (28.6% ± 3.5) and spleen (8.3% ± 1.0) was significantly lower than the binding to bone marrow stromal cells from healthy individuals (39.9% ± 3.1). Binding of XG-1 cells to bone marrow stromal cells from myeloma patients with progressive disease was significantly higher as compared to bone marrow stroma from patients with stable disease or from healthy individuals (56.2% ± 4.2 vs 36.9% ± 6.4 and 39.9% ± 3.1, respectively). The contribution of CD44s (Figure 5a 
Involvement of CD44v9 in production of IL-6 by stromal cells after plasma cell adhesion
IL-6 is the most important growth factor for myeloma cells in vitro and in vivo.
14 Bone marrow stromal cells spontaneously secrete varying amounts of IL-6 7, 12 and adhesion of myeloma plasma cells to stromal cells increases IL-6 production. 7, 12 Antibodies directed against molecules involved in this binding process have been shown to inhibit IL-6 production. 7, 11, 12 A quantitative assessment of IL-6 secretion by stromal cells after binding of IL-6-dependent plasma cells is difficult to make. Therefore, the IL-6-independent CD44v6 − v9
+ plasma cell line NCI-H929 was used to test whether CD44v9-mediated adhesion contributed to the induction of IL-6 secretion by stromal cells. The results presented in Figure 6 show that coculture with NCI-H929 cells increases IL-6 secretion by bone marrow stromal cells 4-5-fold, and addition of antibodies directed against CD44v9 significantly (P Ͻ 0.007) reduced plasma cell-induced IL-6 secretion. Antibodies directed against other adhesion molecules involved in the binding of NCI-H929 cells to stromal cells (anti-CD44s and anti-VLA-4) also partially inhibited plasma cell-induced IL-6 secretion. Antibodies against CD44v6 did not interfere in IL-6 secretion (data not shown).
Discussion
In a previous paper we described that over-expression of domain 9v-containing CD44 isoforms in multiple myeloma correlated with unfavorable prognosis. 16 We speculated about a role for CD44v9 in cellular adhesion contributing to enhanced bone marrow infiltration by plasma cells or in growth regulation, possibly via IL-6 production by cells in the bone marrow environment. The results performed with human plasma cell lines presented here, show that CD44v3, CD44v6 and v9 are preferentially expressed on plasma cells and that CD44v6 and CD44v9 are involved in adhesion to stromal cells. Adhesion of plasma cells triggers IL-6 production by 
Figure 2
Fusion proteins encoded by exons CD44v6 and CD44v8-v9-v10 inhibit binding of plasma cell line XG-1 to bone marrow stromal cells. Fusion proteins encoded by CD44v3-4v, CD44v6, CD44v8-9-10 and CD44v10 were used to block adhesion of plasma cell line XG-1 to bone marrow stromal cells. Inhibition is expressed as mean % inhibition ± s.e.m. The horizontal line represents the level of background binding inhibition as determined by examining CD44-negative cell lines. P values show statistically significant differences in CD44-GST fusion protein blocking as compared to GST protein alone, which did not interfere in plasma cell adhesion (data not shown). n, the number of performed individual experiments. stromal cells and is inhibited by antibodies against CD44v9. These findings show, for the first time, that CD44v can function as adhesion molecules for human plasma cells, and extend earlier studies showing that physical contact between tumor cells and bone marrow stromal cells induce IL-6 secretion. 7, 11, 12 Furthermore, the results presented in this paper show that CD44v9 expression correlates with in vitro IL-6-dependent growth of plasma cell lines. If this holds true for in vivo behavior of myeloma tumor cells these results may explain the previously described correlation between CD44v9 expression and adverse prognosis in multiple myeloma.
Involvement of CD44v molecules in plasma cell adhesion was substantiated by use of adhesion assays employing cell lines negative for CD44 and cell lines expressing CD44v6 and/or CD44v9. Stromal cell binding was inhibited by antiCD44v antibodies only when the relevant CD44v molecule
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Figure 3
CD44v6 and CD44v9 isoforms are involved in plasma cell binding to bone marrow stromal cells but not to ECM or HA. Cells obtained from plasma cell line XG-1 (CD44v6
) were allowed to bind to bone marrow stromal cells (stroma, binding: 56.2% ± 4.2 of the input cells), extracellular matrix components of bone marrow stroma (ECM, binding: 48.2% ± 2.9 of the input cells) and hyaluronic acid (HA, binding: 39.4% ± 3.1 of the input cells). Binding inhibition was quantified (mean % inhibition ± s.e.m.) using antibodies directed against CD44s (␣CD44s), CD44v6 (␣CD44v6), CD44v9 (␣CD44v9) and VLA-4 (␣VLA-4). The horizontal line represents the level of background inhibition, as determined by examining CD44-negative cell lines. P values show statistical significant blocking differences using CD44 antibodies compared to isotype and subclass matched control antibodies. ND, not done; n, the number of performed individual experiments.
Figure 4
Plasma cells show quantitative differences in binding to adherent cells of different origin. Binding of XG-1 plasma cells (as % input cells) to adherent cells of different origin was compared. Adherent cells employed in the adhesion assays were derived from bone marrow from myeloma patients with progressive disease (MM BM (progressive)), bone marrow from myeloma patients with stable disease (MM BM (stable)), bone marrow from healthy individuals (NBM), tonsil and spleen. P values are connected via a line in the graph and indicate statistically significant differences in plasma cell binding to different stromal cells. n, the number of individual experiments performed.
was expressed on the plasma cell lines. The nature of the interaction was further investigated using CD44-GST fusion proteins encoding CD44 exons v6 and v9. These fusion proteins inhibited plasma cell binding to the same extent as the antibodies, whereas fusion proteins encoding exon v3-v4 did not, suggesting that peptide epitopes of CD44 variant regions v6 and v9 are involved in the adhesion of plasma cells to bone marrow stromal cells. Adherent cell layers employed in these studies did not express CD44v6 or CD44v9 (data not shown). Inhibition was, therefore, most likely the result of interference between CD44v expressed on the plasma cells and ligands present on the bone marrow stromal cells. At present it is unclear whether v6 and v9 are involved in the same or separate adhesion pathways. Simultaneous blocking with anti-CD44s and CD44v6 or CD44s and CD44v9 resulted in an additive effect, when a combination of anti-CD44v6 and CD44v9 was used, however, no enhanced adhesion inhibition was observed as compared to the antibodies alone.
Several ligands for CD44 molecules have been described (reviewed in Refs 18, 51, 52) and include ECM components HA, fibronectin, collagen, osteopontin, serglycin and the invariant chain (Ii) of MHC class II molecules. HA is the principal ligand for CD44s, 29 it is a polysaccharide with a high molecular mass, abundantly present in ECM, which binds to the amino terminal portion of the CD44 molecule. 53 Both CD44s and CD44v are capable of binding to HA, although this depends on the isoform and the cell type on which the CD44 molecules are expressed. 54 We addressed the question as to whether CD44v-mediated plasma cell adhesion to bone marrow stromal cells could be attributed to binding of CD44v to HA in in vitro synthesized ECM. Plasma cell lines positive for CD44 showed variable binding to HA immobilized to plastic, where it was found that some bound very well (XG-1), whereas others did not bind at all (U266 (data not shown)). These differences may be attributed to differences in expression level, but also post-translational modifications of CD44. Both glycosylation and chondroitin sulphate addition 51,55-57 have been described as regulating HA binding. Anti-CD44s antibodies, but not antibodies directed against CD44v6 or v9, blocked the binding of plasma cell lines to immobilized HA, which implies that CD44v6 and v9, expressed on plasma cells, are not involved in HA binding. This is additionally illustrated by the finding that U266, which is a CD44v9 + plasma cell line, did not bind to HA, while the binding to bone marrow stromal cells was inhibited by antiCD44v9. These results imply that the binding to HA and CD44v9 to bone marrow stromal cells constitute different adhesion pathways. CD44v molecules can also bind to matrix components such as fibronectin and collagen, [30] [31] [32] possibly mediated by chondroitin sulphate moieties associated with CD44 isoforms containing exon v10. 58, 59 Binding of XG-1 plasma cells to in vitro synthesized ECM derived from bone marrow adherent cells, however, depended largely on VLA-4 -fibronectin and CD44s -HA interaction. CD44v-specific antibodies used in this study did not interfere with ECM binding. The procedure employed to obtain ECM removes adherent cells and leaves matrix components such as fibronectin, laminin, von Willebrand factor and collagens intact for binding to adhesive receptors expressed on cells. [46] [47] [48] Although we cannot formally exclude the possibility that Triton X-100 treatment removes potential ligand(s) for CD44v6 and CD44v9 from the matrix selectively and completely, these data collectively suggest that both CD44v6 and CD44v9 are involved in cell-cell interaction, rather than binding to matrix components.
The molecular basis for preferential localization and expansion of myeloma plasma cells in bone marrow is obscure, but may be the consequence of selective binding and/or growth of the tumor cells. Mice were used for in vivo studies in which transfected lymphoma cells expressing large 9v-containing . Adherent cells employed in adhesion assays were derived from bone marrow from myeloma patients with progressive disease (MM BM (progressive), bone marrow from myeloma patients with stable disease (MM BM (stable)), bone marrow from healthy individuals (NBM), tonsil and spleen. P values show statistically significant differences in blocking using anti-CD44 or anti-VLA-4 antibodies as compared to isotype and subclass matched control antibodies; n, the number of individual experiments performed.
Figure 6
CD44v9 is involved in adhesion-induced IL-6 production by bone marrow stromal cells. IL-6 secretion was induced after binding of the IL-6-independent CD44v6 − v9
+ plasma cell line NCI-H929 to bone marrow stromal cells, in the presence of isotype and subclass matched antibodies (stroma + NCI-H929). Addition of antibodies directed against CD44v9 significantly inhibited (P Ͻ 0.007) the induction of IL-6 production (stroma + NCI-H929 + antiCD44v9). No differences were observed in spontaneous IL-6 production by stromal cells in the absence (stroma) or presence of anti-CD44v9 antibodies (stroma + anti-CD449). One out of three representative experiments is shown.
Leukemia isoforms, showed a preferential growth and dissemination to BM. 60 Here, we show that CD44v9 isoforms are not exclusively employed in the binding to bone marrow stromal cells, but are also involved in plasma cell binding to stromal cells obtained from tonsil and spleen. However, large differences were found in quantitative binding. XG-1 plasma cells adhered most avidly to bone marrow stromal cells, followed by stromal cells obtained from tonsil and spleen, respectively. Furthermore, binding of XG-1 cells to bone marrow stromal cells obtained from myeloma patients with progressive disease, was significantly higher compared to those of healthy individuals and myeloma patients with stable disease. The molecular basis for the observed difference is unknown at present. Stromal cells from normal bone marrow and myeloma patients with progressive disease, however, differ in their spontaneous secretion of cytokines, even after prolonged in vitro culture. 7, 61, 62 Since adhesion is subject to regulation via cytokines, the differences in cytokine profiles may contribute to differences in adhesive behavior of the stromal cells. Although these data from in vitro adhesion experiments have to be interpreted with caution, they show quantitative differences in binding to identically cultured stromal cells derived from different tissues and these differences possibly contribute to preferential in vivo localization of plasma cells.
In summary, we have presented evidence that CD44v3, CD44v6 and CD44v9 are preferentially expressed on plasma cell lines and involved in adhesion of plasma cells to stromal cells from different tissues. The possible relationship between IL-6R expression and CD44v9 expression on plasma cells warrants further investigation and may be a first step in the elucidation of the previously described correlation between CD44v9 expression and adverse prognosis in multiple myeloma.
